<DOC>
	<DOCNO>NCT01613677</DOCNO>
	<brief_summary>This single arm open label phase II trial evaluate oral daily use BKM 120 patient recurrent unresectable metastatic cervical cancer palliative cisplatin base regimen failure . A complete treatment cycle define 28 day period .</brief_summary>
	<brief_title>Phase II , Open Label , Non-randomized , Trial BKM120 Metastatic Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>Inclusion exclusion criterion assess pretreatment visit inform consent must take treatment assignment . The diagnosis extent disease , medical history , current medical condition record investigator pretreatment visit . Adverse event record include type , severity , grade CTCAE V 3.0 , seriousness potential relation investigational drug . The efficacy assessment do MRI record patient ' clinical chart . Tumor dimension assessment perform baseline abdominal/pelvic magnetic resonance imaging , repeat 3 month interval evaluate accord RECIST criterion . The first cohort , compose 06 first patient , undergo separate positron-emission tomography ( PET-CT ) evaluation baseline 90 day apart . Laboratory test ( hematology , blood chemistry ) , ECG physical examination do every visit . Drug pharmacokinetics assess study . For screen Baseline period , see chart attach The treatment continue progressive disease intolerable toxicity</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Patient provide sign Informed Consent Form ( ICF ) obtain prior screening procedure . Female 18 year age old . Histologically cytologically confirm recurrent unresectable metastatic cervix squamouscell carcinoma . ECOG performance status 02 Adequate renal , hepatic hematologic function : ANC ≥1250/mm3 ; Platelet count ≥100,000/mm3 ; Hemoglobin ≥ 9.0 g/dL Creatinine ≤1.5X upper limit normal 24 hrs clearance ≥55ml/min ; Serum bilirubin within normal range ( ≤ 1.5 x ULN liver metastases present ; total bilirubin ≤ 3.0 x ULN direct bilirubin within normal range patient well document Gilbert Syndrome ) SGOT , SGPT ≤ 1.5 X upper limit normal liver metastasis present ; SGOT , SGPT , alkaline phosphatase ≤ 3 X upper limit normal liver metastasis present ; Measurable disease magnetic resonance image accord RECIST criterion . Willingness capacity understand comply trial planned procedure , include periodic medical visit , treatment plan laboratory test . Negative serum pregnancy test screen negative urinary test pregnancy within 48 hour start study treatment woman childbearing potential Previous use PI3K inhibitor . Brain spinal cord compressive metastasis . Patients appropriately treat brain spinal metastasis neurologically stable least 4 week include discretion investigator . Concurrent malignancy nonmelanoma skin cancer . Concurrent clinical condition impeditive part study judgment investigator . Patient follow mood disorder judge Investigator Psychiatrist , meet cutoff score ≥ 10 PHQ9 cutoff ≥ 15 GAD7 mood scale , respectively , selects positive response ' 1 , 2 , 3 ' question number 9 regard potential suicidal thought ideation PHQ9 ( independent total score PHQ9 ) : Medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( immediate risk harm others ) ≥ CTCAE grade 3 anxiety Patients acute chronic liver , renal disease pancreatitis . Patients diarrhea ≥ CTCAE grade 2 . Any following concurrent severe and/or uncontrolled medical condition could compromise participation study : ST depression elevation ≥ 1.5 mm 2 lead ; Congenital long QT syndrome ; History presence sustain ventricular arrhythmia atrial fibrillation ; Clinically significant rest bradycardia ( &lt; 50 beat per minute ) ; QTc &gt; 480 msec screen ECG ; Complete leave bundle branch block ; Right bundle branch block + leave anterior hemi block ( bifascicular block ) ; Unstable angina pectoris ≤ 6 month prior start study drug ; Acute myocardial infarction ≤ 6 month prior start study drug ; Other clinically significant heart disease congestive heart failure require treatment ( NYHA Class III IV ) uncontrolled hypertension ; Patients clinical manifestation diabetes mellitus ( i.e . treat and/or clinical sign ) steroidinduced diabetes mellitus uncontrolled diabetes ( Fasting glucose &gt; 120 mg/dL ( HbA1c &gt; 8 % ) . Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g. , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BKM120 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Patients receive corticosteroid ≤ 2 week prior start study drug . Patient currently treat drug know moderate strong inhibitor inducer isoenzyme CYP3A , treatment discontinue switched different medication prior start study drug . Please refer Table 58 list prohibit CYP3A4 inhibitor inducer . Employing effective method birth control . ( Women childbearing potential , define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) , must negative serum pregnancy test screen negative urinary test pregnancy within 48 hour start study treatment woman childbearing potential ) . Known diagnosis human immunodeficiency virus ( HIV ) infection . Patient unable unwilling abide study protocol cooperate fully investigator . Patient receive pelvic and/or paraaortic radiotherapy ≤ 28 day prior enrollment study recover side effect therapy time initiation screen procedure MRI study additional exclusion consider MRI study Cardiac pacemaker Ferromagnetic metal implant approve safe use MR scanner ( Example : type aneurysm clip , schrapnel ) Claustrophobia Obesity ( exceed equipment limit )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>advanced cervical cancer , BKM 120 , progression free survival</keyword>
</DOC>